Brokerages Set Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Target Price at $48.00

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has earned an average rating of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $48.00.

A number of research firms have recently weighed in on SNSE. Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price on the stock. BTIG Research started coverage on Sensei Biotherapeutics in a research note on Thursday, June 11th. They issued a “buy” rating and a $55.00 price target for the company. Finally, Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st.

Sensei Biotherapeutics Trading Up 2.1%

Shares of SNSE stock opened at $14.14 on Friday. The company has a market capitalization of $18.98 million, a PE ratio of -0.10 and a beta of -0.25. The firm has a fifty day simple moving average of $16.20 and a 200-day simple moving average of $19.76. Sensei Biotherapeutics has a twelve month low of $5.86 and a twelve month high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83).

Insider Buying and Selling at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its holdings in shares of Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the period. Bank of America Corp DE lifted its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Finally, Vivo Capital LLC bought a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth about $22,758,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.